MAIA Biotechnology, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the SEC on November 9, 2026, reporting condensed consolidated balance sheet data showing a significant increase in cash and a wider accumulated deficit.

Key Highlights

  • Cash position: Cash stood at $21,338,931 as of September 30, 2026, up from $8,658,031 at December 31, 2025, according to the filing.
  • Total assets: Total assets were reported at $22,100,552 as of September 30, 2026, compared with $9,704,656 at December 31, 2025.
  • Accumulated deficit: The accumulated deficit widened to $131,122,381 as of September 30, 2026, from $109,631,005 at December 31, 2025.
  • Shares outstanding: Common shares issued and outstanding increased to 61,741,946 at September 30, 2026, from 38,624,289 at December 31, 2025.
  • Subscription receivable: A subscription receivable of $(1,000,000) appeared on the balance sheet as of September 30, 2026, with no comparable balance at December 31, 2025.
  • Total stockholders' equity: Total stockholders' equity was $14,669,600 at September 30, 2026, up from $2,375,863 at December 31, 2025.
  • Shares outstanding at filing date: As of November 9, 2026, the registrant reported 61,750,308 shares of common stock outstanding.

MAIA Biotechnology Balance Sheet Position as of September 30, 2026

According to the filing, MAIA Biotechnology, Inc. (NYSE American:MAIA) reported total assets of $22,100,552 as of September 30, 2026, a substantial increase from $9,704,656 at December 31, 2025. The primary driver of that increase, the company disclosed, was a rise in cash from $8,658,031 to $21,338,931. Prepaid expenses and other current assets declined from $1,043,825 to $758,821 over the same period.

On the liabilities side, the filing reported total current liabilities of $6,473,965 at September 30, 2026, compared with $5,836,398 at December 31, 2025. Accounts payable rose to $4,121,145 from $2,038,803, while accrued expenses fell to $2,352,820 from $3,797,595. A warrant liability of $956,987 was recorded as a long-term liability, down from $1,492,395 at December 31, 2025.

The company's stockholders' equity position improved to $14,669,600 from $2,375,863, though the accumulated deficit widened by approximately $21.5 million to $131,122,381. The share count growth, from 38,624,289 to 61,741,946 shares issued and outstanding, contributed to an increase in additional paid-in capital to $146,774,827 from $112,053,233, the filing disclosed. MAIA Biotechnology is classified as a non-accelerated filer, smaller reporting company, and emerging growth company, as indicated on the filing's cover page.

What Was Disclosed

MAIA Biotechnology filed its quarterly report covering the period ended September 30, 2026, disclosing balance sheet data that included a cash increase to $21,338,931, a widening accumulated deficit of $131,122,381, and a rise in shares outstanding to 61,741,946 as of the quarter end.